nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2C8—Spironolactone—dilated cardiomyopathy	0.168	0.409	CbGbCtD
Paroxetine—ABCB1—Lisinopril—dilated cardiomyopathy	0.129	0.314	CbGbCtD
Paroxetine—ABCB1—Spironolactone—dilated cardiomyopathy	0.114	0.277	CbGbCtD
Paroxetine—CYP2C9—cardial valve—dilated cardiomyopathy	0.018	0.404	CbGeAlD
Paroxetine—SLC6A2—sympathetic nervous system—dilated cardiomyopathy	0.00969	0.218	CbGeAlD
Paroxetine—HTR2A—pulmonary artery—dilated cardiomyopathy	0.00599	0.135	CbGeAlD
Paroxetine—HTR2A—sympathetic nervous system—dilated cardiomyopathy	0.00583	0.131	CbGeAlD
Paroxetine—CHRM2—heart—dilated cardiomyopathy	0.00169	0.038	CbGeAlD
Paroxetine—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00156	0.00396	CcSEcCtD
Paroxetine—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.00154	0.00392	CcSEcCtD
Paroxetine—Gout—Lisinopril—dilated cardiomyopathy	0.00154	0.00392	CcSEcCtD
Paroxetine—Leukocytosis—Lisinopril—dilated cardiomyopathy	0.00153	0.0039	CcSEcCtD
Paroxetine—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00148	0.00377	CcSEcCtD
Paroxetine—Dermatitis exfoliative—Furosemide—dilated cardiomyopathy	0.00148	0.00375	CcSEcCtD
Paroxetine—Thirst—Furosemide—dilated cardiomyopathy	0.00146	0.00372	CcSEcCtD
Paroxetine—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00146	0.00371	CcSEcCtD
Paroxetine—Neck pain—Lisinopril—dilated cardiomyopathy	0.00146	0.00371	CcSEcCtD
Paroxetine—Purpura—Furosemide—dilated cardiomyopathy	0.00145	0.00367	CcSEcCtD
Paroxetine—Pulmonary embolism—Lisinopril—dilated cardiomyopathy	0.00144	0.00366	CcSEcCtD
Paroxetine—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00144	0.00366	CcSEcCtD
Paroxetine—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00144	0.00366	CcSEcCtD
Paroxetine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00143	0.00364	CcSEcCtD
Paroxetine—Lethargy—Furosemide—dilated cardiomyopathy	0.00142	0.00361	CcSEcCtD
Paroxetine—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.00142	0.0036	CcSEcCtD
Paroxetine—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00141	0.00358	CcSEcCtD
Paroxetine—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.0014	0.00356	CcSEcCtD
Paroxetine—Salivary hypersecretion—Lisinopril—dilated cardiomyopathy	0.0014	0.00356	CcSEcCtD
Paroxetine—Malaise—Spironolactone—dilated cardiomyopathy	0.00139	0.00354	CcSEcCtD
Paroxetine—Cystitis—Lisinopril—dilated cardiomyopathy	0.00139	0.00354	CcSEcCtD
Paroxetine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00138	0.00351	CcSEcCtD
Paroxetine—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00137	0.00348	CcSEcCtD
Paroxetine—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00136	0.00346	CcSEcCtD
Paroxetine—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00135	0.00344	CcSEcCtD
Paroxetine—Photophobia—Lisinopril—dilated cardiomyopathy	0.00135	0.00344	CcSEcCtD
Paroxetine—Urinary retention—Furosemide—dilated cardiomyopathy	0.00133	0.00337	CcSEcCtD
Paroxetine—Bladder pain—Lisinopril—dilated cardiomyopathy	0.0013	0.00331	CcSEcCtD
Paroxetine—Discomfort—Spironolactone—dilated cardiomyopathy	0.0013	0.0033	CcSEcCtD
Paroxetine—Dehydration—Furosemide—dilated cardiomyopathy	0.0013	0.00329	CcSEcCtD
Paroxetine—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.00129	0.00328	CcSEcCtD
Paroxetine—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00128	0.00326	CcSEcCtD
Paroxetine—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.00127	0.00324	CcSEcCtD
Paroxetine—Confusional state—Spironolactone—dilated cardiomyopathy	0.00127	0.00323	CcSEcCtD
Paroxetine—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00127	0.00322	CcSEcCtD
Paroxetine—Hypertonia—Lisinopril—dilated cardiomyopathy	0.00126	0.00321	CcSEcCtD
Paroxetine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00126	0.0032	CcSEcCtD
Paroxetine—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00126	0.00319	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00126	0.00319	CcSEcCtD
Paroxetine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00123	0.00313	CcSEcCtD
Paroxetine—Muscular weakness—Furosemide—dilated cardiomyopathy	0.00123	0.00312	CcSEcCtD
Paroxetine—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00121	0.00307	CcSEcCtD
Paroxetine—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.0012	0.00306	CcSEcCtD
Paroxetine—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.0012	0.00304	CcSEcCtD
Paroxetine—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00119	0.00303	CcSEcCtD
Paroxetine—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00119	0.00303	CcSEcCtD
Paroxetine—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00118	0.003	CcSEcCtD
Paroxetine—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00118	0.003	CcSEcCtD
Paroxetine—Eczema—Lisinopril—dilated cardiomyopathy	0.00116	0.00296	CcSEcCtD
Paroxetine—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00116	0.00296	CcSEcCtD
Paroxetine—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.00116	0.00294	CcSEcCtD
Paroxetine—Injury—Lisinopril—dilated cardiomyopathy	0.00114	0.00289	CcSEcCtD
Paroxetine—Renal failure acute—Lisinopril—dilated cardiomyopathy	0.00113	0.00288	CcSEcCtD
Paroxetine—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00113	0.00287	CcSEcCtD
Paroxetine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00112	0.00284	CcSEcCtD
Paroxetine—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00111	0.00283	CcSEcCtD
Paroxetine—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.0011	0.0028	CcSEcCtD
Paroxetine—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.0011	0.00279	CcSEcCtD
Paroxetine—Renal impairment—Lisinopril—dilated cardiomyopathy	0.0011	0.00279	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00109	0.00276	CcSEcCtD
Paroxetine—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00109	0.00276	CcSEcCtD
Paroxetine—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00108	0.00275	CcSEcCtD
Paroxetine—Arthritis—Lisinopril—dilated cardiomyopathy	0.00108	0.00273	CcSEcCtD
Paroxetine—Drowsiness—Furosemide—dilated cardiomyopathy	0.00107	0.00273	CcSEcCtD
Paroxetine—Hypoglycaemia—Lisinopril—dilated cardiomyopathy	0.00107	0.00272	CcSEcCtD
Paroxetine—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00107	0.00271	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00107	0.00271	CcSEcCtD
Paroxetine—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00105	0.00267	CcSEcCtD
Paroxetine—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00105	0.00266	CcSEcCtD
Paroxetine—Diplopia—Lisinopril—dilated cardiomyopathy	0.00105	0.00266	CcSEcCtD
Paroxetine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00104	0.00264	CcSEcCtD
Paroxetine—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00104	0.00264	CcSEcCtD
Paroxetine—Sweating—Furosemide—dilated cardiomyopathy	0.00103	0.00262	CcSEcCtD
Paroxetine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00102	0.00258	CcSEcCtD
Paroxetine—Face oedema—Lisinopril—dilated cardiomyopathy	0.00101	0.00257	CcSEcCtD
Paroxetine—CYP2B6—heart—dilated cardiomyopathy	0.001	0.0225	CbGeAlD
Paroxetine—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.001	0.00255	CcSEcCtD
Paroxetine—Urticaria—Spironolactone—dilated cardiomyopathy	0.001	0.00254	CcSEcCtD
Paroxetine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000996	0.00253	CcSEcCtD
Paroxetine—CYP2C9—heart—dilated cardiomyopathy	0.000993	0.0223	CbGeAlD
Paroxetine—Ataxia—Lisinopril—dilated cardiomyopathy	0.000984	0.0025	CcSEcCtD
Paroxetine—Dehydration—Lisinopril—dilated cardiomyopathy	0.000973	0.00247	CcSEcCtD
Paroxetine—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.000955	0.00243	CcSEcCtD
Paroxetine—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000945	0.0024	CcSEcCtD
Paroxetine—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000942	0.00239	CcSEcCtD
Paroxetine—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000942	0.00239	CcSEcCtD
Paroxetine—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.000935	0.00238	CcSEcCtD
Paroxetine—Visual impairment—Furosemide—dilated cardiomyopathy	0.000929	0.00236	CcSEcCtD
Paroxetine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000928	0.00236	CcSEcCtD
Paroxetine—Gastritis—Lisinopril—dilated cardiomyopathy	0.000926	0.00235	CcSEcCtD
Paroxetine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.000912	0.00232	CcSEcCtD
Paroxetine—Influenza—Lisinopril—dilated cardiomyopathy	0.000904	0.0023	CcSEcCtD
Paroxetine—Asthma—Lisinopril—dilated cardiomyopathy	0.000904	0.0023	CcSEcCtD
Paroxetine—Eye disorder—Furosemide—dilated cardiomyopathy	0.000901	0.00229	CcSEcCtD
Paroxetine—Tinnitus—Furosemide—dilated cardiomyopathy	0.000899	0.00228	CcSEcCtD
Paroxetine—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.000895	0.00227	CcSEcCtD
Paroxetine—Pruritus—Spironolactone—dilated cardiomyopathy	0.000891	0.00226	CcSEcCtD
Paroxetine—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000886	0.00225	CcSEcCtD
Paroxetine—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000881	0.00224	CcSEcCtD
Paroxetine—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000881	0.00224	CcSEcCtD
Paroxetine—Angiopathy—Furosemide—dilated cardiomyopathy	0.000875	0.00222	CcSEcCtD
Paroxetine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000871	0.00221	CcSEcCtD
Paroxetine—Bronchitis—Lisinopril—dilated cardiomyopathy	0.000869	0.00221	CcSEcCtD
Paroxetine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000862	0.00219	CcSEcCtD
Paroxetine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000862	0.00219	CcSEcCtD
Paroxetine—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.000859	0.00218	CcSEcCtD
Paroxetine—Dysuria—Lisinopril—dilated cardiomyopathy	0.000845	0.00215	CcSEcCtD
Paroxetine—Malnutrition—Furosemide—dilated cardiomyopathy	0.00084	0.00213	CcSEcCtD
Paroxetine—Erythema—Furosemide—dilated cardiomyopathy	0.00084	0.00213	CcSEcCtD
Paroxetine—Dizziness—Spironolactone—dilated cardiomyopathy	0.000833	0.00212	CcSEcCtD
Paroxetine—Erectile dysfunction—Lisinopril—dilated cardiomyopathy	0.000833	0.00212	CcSEcCtD
Paroxetine—Flatulence—Furosemide—dilated cardiomyopathy	0.000827	0.0021	CcSEcCtD
Paroxetine—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000825	0.0021	CcSEcCtD
Paroxetine—Weight increased—Lisinopril—dilated cardiomyopathy	0.000823	0.00209	CcSEcCtD
Paroxetine—Dysgeusia—Furosemide—dilated cardiomyopathy	0.000822	0.00209	CcSEcCtD
Paroxetine—Weight decreased—Lisinopril—dilated cardiomyopathy	0.000818	0.00208	CcSEcCtD
Paroxetine—HTR2A—heart—dilated cardiomyopathy	0.000818	0.0184	CbGeAlD
Paroxetine—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000816	0.00207	CcSEcCtD
Paroxetine—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000811	0.00206	CcSEcCtD
Paroxetine—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000807	0.00205	CcSEcCtD
Paroxetine—Depression—Lisinopril—dilated cardiomyopathy	0.000804	0.00204	CcSEcCtD
Paroxetine—Vomiting—Spironolactone—dilated cardiomyopathy	0.000801	0.00203	CcSEcCtD
Paroxetine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.000799	0.00203	CcSEcCtD
Paroxetine—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000795	0.00202	CcSEcCtD
Paroxetine—Rash—Spironolactone—dilated cardiomyopathy	0.000794	0.00202	CcSEcCtD
Paroxetine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000793	0.00202	CcSEcCtD
Paroxetine—Vision blurred—Furosemide—dilated cardiomyopathy	0.000791	0.00201	CcSEcCtD
Paroxetine—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00079	0.00201	CcSEcCtD
Paroxetine—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00079	0.00201	CcSEcCtD
Paroxetine—Headache—Spironolactone—dilated cardiomyopathy	0.000789	0.002	CcSEcCtD
Paroxetine—Jaundice—Lisinopril—dilated cardiomyopathy	0.000786	0.002	CcSEcCtD
Paroxetine—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.000784	0.00199	CcSEcCtD
Paroxetine—Anaemia—Furosemide—dilated cardiomyopathy	0.000776	0.00197	CcSEcCtD
Paroxetine—Sweating—Lisinopril—dilated cardiomyopathy	0.000773	0.00196	CcSEcCtD
Paroxetine—Agitation—Furosemide—dilated cardiomyopathy	0.000772	0.00196	CcSEcCtD
Paroxetine—Haematuria—Lisinopril—dilated cardiomyopathy	0.000769	0.00195	CcSEcCtD
Paroxetine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000762	0.00194	CcSEcCtD
Paroxetine—Epistaxis—Lisinopril—dilated cardiomyopathy	0.00076	0.00193	CcSEcCtD
Paroxetine—Sinusitis—Lisinopril—dilated cardiomyopathy	0.000756	0.00192	CcSEcCtD
Paroxetine—Vertigo—Furosemide—dilated cardiomyopathy	0.000754	0.00192	CcSEcCtD
Paroxetine—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000752	0.00191	CcSEcCtD
Paroxetine—Leukopenia—Furosemide—dilated cardiomyopathy	0.000752	0.00191	CcSEcCtD
Paroxetine—Nausea—Spironolactone—dilated cardiomyopathy	0.000748	0.0019	CcSEcCtD
Paroxetine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000737	0.00187	CcSEcCtD
Paroxetine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.000725	0.00184	CcSEcCtD
Paroxetine—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000724	0.00184	CcSEcCtD
Paroxetine—Hallucination—Lisinopril—dilated cardiomyopathy	0.00072	0.00183	CcSEcCtD
Paroxetine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000718	0.00182	CcSEcCtD
Paroxetine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000713	0.00181	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00071	0.0018	CcSEcCtD
Paroxetine—Dry mouth—Furosemide—dilated cardiomyopathy	0.000699	0.00178	CcSEcCtD
Paroxetine—Confusional state—Furosemide—dilated cardiomyopathy	0.000691	0.00176	CcSEcCtD
Paroxetine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000685	0.00174	CcSEcCtD
Paroxetine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.000684	0.00174	CcSEcCtD
Paroxetine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000675	0.00171	CcSEcCtD
Paroxetine—Shock—Furosemide—dilated cardiomyopathy	0.000674	0.00171	CcSEcCtD
Paroxetine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000672	0.00171	CcSEcCtD
Paroxetine—Flushing—Lisinopril—dilated cardiomyopathy	0.000672	0.00171	CcSEcCtD
Paroxetine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000671	0.0017	CcSEcCtD
Paroxetine—Skin disorder—Furosemide—dilated cardiomyopathy	0.000666	0.00169	CcSEcCtD
Paroxetine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000662	0.00168	CcSEcCtD
Paroxetine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000657	0.00167	CcSEcCtD
Paroxetine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000652	0.00166	CcSEcCtD
Paroxetine—Chills—Lisinopril—dilated cardiomyopathy	0.000649	0.00165	CcSEcCtD
Paroxetine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000646	0.00164	CcSEcCtD
Paroxetine—Hypotension—Furosemide—dilated cardiomyopathy	0.00064	0.00163	CcSEcCtD
Paroxetine—Alopecia—Lisinopril—dilated cardiomyopathy	0.000639	0.00162	CcSEcCtD
Paroxetine—Mental disorder—Lisinopril—dilated cardiomyopathy	0.000634	0.00161	CcSEcCtD
Paroxetine—Erythema—Lisinopril—dilated cardiomyopathy	0.00063	0.0016	CcSEcCtD
Paroxetine—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00063	0.0016	CcSEcCtD
Paroxetine—Flatulence—Lisinopril—dilated cardiomyopathy	0.000621	0.00158	CcSEcCtD
Paroxetine—Tension—Lisinopril—dilated cardiomyopathy	0.000618	0.00157	CcSEcCtD
Paroxetine—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000617	0.00157	CcSEcCtD
Paroxetine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000615	0.00156	CcSEcCtD
Paroxetine—Nervousness—Lisinopril—dilated cardiomyopathy	0.000612	0.00155	CcSEcCtD
Paroxetine—Back pain—Lisinopril—dilated cardiomyopathy	0.000609	0.00155	CcSEcCtD
Paroxetine—Somnolence—Furosemide—dilated cardiomyopathy	0.000609	0.00155	CcSEcCtD
Paroxetine—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000606	0.00154	CcSEcCtD
Paroxetine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000596	0.00151	CcSEcCtD
Paroxetine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000594	0.00151	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.000592	0.0015	CcSEcCtD
Paroxetine—Fatigue—Furosemide—dilated cardiomyopathy	0.000591	0.0015	CcSEcCtD
Paroxetine—Tremor—Lisinopril—dilated cardiomyopathy	0.00059	0.0015	CcSEcCtD
Paroxetine—Pain—Furosemide—dilated cardiomyopathy	0.000586	0.00149	CcSEcCtD
Paroxetine—Constipation—Furosemide—dilated cardiomyopathy	0.000586	0.00149	CcSEcCtD
Paroxetine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000584	0.00148	CcSEcCtD
Paroxetine—Anaemia—Lisinopril—dilated cardiomyopathy	0.000582	0.00148	CcSEcCtD
Paroxetine—Angioedema—Lisinopril—dilated cardiomyopathy	0.000576	0.00146	CcSEcCtD
Paroxetine—Malaise—Lisinopril—dilated cardiomyopathy	0.000568	0.00144	CcSEcCtD
Paroxetine—Vertigo—Lisinopril—dilated cardiomyopathy	0.000566	0.00144	CcSEcCtD
Paroxetine—Syncope—Lisinopril—dilated cardiomyopathy	0.000565	0.00144	CcSEcCtD
Paroxetine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000565	0.00143	CcSEcCtD
Paroxetine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000564	0.00143	CcSEcCtD
Paroxetine—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00056	0.00142	CcSEcCtD
Paroxetine—Palpitations—Lisinopril—dilated cardiomyopathy	0.000557	0.00141	CcSEcCtD
Paroxetine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.000554	0.00141	CcSEcCtD
Paroxetine—Cough—Lisinopril—dilated cardiomyopathy	0.00055	0.0014	CcSEcCtD
Paroxetine—Urticaria—Furosemide—dilated cardiomyopathy	0.000544	0.00138	CcSEcCtD
Paroxetine—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000542	0.00138	CcSEcCtD
Paroxetine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000542	0.00138	CcSEcCtD
Paroxetine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000536	0.00136	CcSEcCtD
Paroxetine—Chest pain—Lisinopril—dilated cardiomyopathy	0.000536	0.00136	CcSEcCtD
Paroxetine—Myalgia—Lisinopril—dilated cardiomyopathy	0.000536	0.00136	CcSEcCtD
Paroxetine—ABCB1—heart—dilated cardiomyopathy	0.000536	0.012	CbGeAlD
Paroxetine—Anxiety—Lisinopril—dilated cardiomyopathy	0.000534	0.00136	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000533	0.00135	CcSEcCtD
Paroxetine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00053	0.00135	CcSEcCtD
Paroxetine—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000525	0.00133	CcSEcCtD
Paroxetine—Confusional state—Lisinopril—dilated cardiomyopathy	0.000518	0.00132	CcSEcCtD
Paroxetine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000514	0.00131	CcSEcCtD
Paroxetine—Oedema—Lisinopril—dilated cardiomyopathy	0.000514	0.00131	CcSEcCtD
Paroxetine—Infection—Lisinopril—dilated cardiomyopathy	0.000511	0.0013	CcSEcCtD
Paroxetine—Shock—Lisinopril—dilated cardiomyopathy	0.000506	0.00129	CcSEcCtD
Paroxetine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000505	0.00128	CcSEcCtD
Paroxetine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000503	0.00128	CcSEcCtD
Paroxetine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000502	0.00127	CcSEcCtD
Paroxetine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000499	0.00127	CcSEcCtD
Paroxetine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.000497	0.00126	CcSEcCtD
Paroxetine—Asthenia—Furosemide—dilated cardiomyopathy	0.000492	0.00125	CcSEcCtD
Paroxetine—Pruritus—Furosemide—dilated cardiomyopathy	0.000485	0.00123	CcSEcCtD
Paroxetine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00048	0.00122	CcSEcCtD
Paroxetine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000469	0.00119	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000468	0.00119	CcSEcCtD
Paroxetine—Insomnia—Lisinopril—dilated cardiomyopathy	0.000465	0.00118	CcSEcCtD
Paroxetine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000462	0.00117	CcSEcCtD
Paroxetine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.000458	0.00116	CcSEcCtD
Paroxetine—Somnolence—Lisinopril—dilated cardiomyopathy	0.000457	0.00116	CcSEcCtD
Paroxetine—Dizziness—Furosemide—dilated cardiomyopathy	0.000453	0.00115	CcSEcCtD
Paroxetine—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000453	0.00115	CcSEcCtD
Paroxetine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000447	0.00114	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000444	0.00113	CcSEcCtD
Paroxetine—Fatigue—Lisinopril—dilated cardiomyopathy	0.000443	0.00113	CcSEcCtD
Paroxetine—Pain—Lisinopril—dilated cardiomyopathy	0.00044	0.00112	CcSEcCtD
Paroxetine—Constipation—Lisinopril—dilated cardiomyopathy	0.00044	0.00112	CcSEcCtD
Paroxetine—Vomiting—Furosemide—dilated cardiomyopathy	0.000436	0.00111	CcSEcCtD
Paroxetine—Rash—Furosemide—dilated cardiomyopathy	0.000432	0.0011	CcSEcCtD
Paroxetine—Dermatitis—Furosemide—dilated cardiomyopathy	0.000432	0.0011	CcSEcCtD
Paroxetine—Headache—Furosemide—dilated cardiomyopathy	0.000429	0.00109	CcSEcCtD
Paroxetine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000424	0.00108	CcSEcCtD
Paroxetine—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00042	0.00107	CcSEcCtD
Paroxetine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000408	0.00104	CcSEcCtD
Paroxetine—Nausea—Furosemide—dilated cardiomyopathy	0.000407	0.00103	CcSEcCtD
Paroxetine—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000406	0.00103	CcSEcCtD
Paroxetine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000406	0.00103	CcSEcCtD
Paroxetine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000379	0.000962	CcSEcCtD
Paroxetine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000369	0.000937	CcSEcCtD
Paroxetine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000364	0.000924	CcSEcCtD
Paroxetine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000352	0.000894	CcSEcCtD
Paroxetine—Dizziness—Lisinopril—dilated cardiomyopathy	0.00034	0.000864	CcSEcCtD
Paroxetine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000327	0.00083	CcSEcCtD
Paroxetine—Rash—Lisinopril—dilated cardiomyopathy	0.000324	0.000824	CcSEcCtD
Paroxetine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000324	0.000823	CcSEcCtD
Paroxetine—Headache—Lisinopril—dilated cardiomyopathy	0.000322	0.000818	CcSEcCtD
Paroxetine—Nausea—Lisinopril—dilated cardiomyopathy	0.000305	0.000776	CcSEcCtD
Paroxetine—HTR2A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000108	0.000718	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000108	0.000714	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000108	0.000713	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000108	0.000713	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000108	0.000712	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000107	0.000707	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000106	0.000705	CbGpPWpGaD
Paroxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000106	0.000699	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000106	0.000699	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000105	0.000697	CbGpPWpGaD
Paroxetine—CHRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000105	0.000695	CbGpPWpGaD
Paroxetine—CHRM3—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000105	0.000693	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000105	0.000692	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—SDHA—dilated cardiomyopathy	0.000104	0.000691	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	0.000104	0.000688	CbGpPWpGaD
Paroxetine—CHRM2—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000104	0.000687	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000103	0.000683	CbGpPWpGaD
Paroxetine—SLC6A3—Neuronal System—RAF1—dilated cardiomyopathy	0.000102	0.000673	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000101	0.000671	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.0001	0.000663	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	9.9e-05	0.000655	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	9.85e-05	0.000652	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	9.82e-05	0.00065	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	9.78e-05	0.000647	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—ADRB1—dilated cardiomyopathy	9.7e-05	0.000642	CbGpPWpGaD
Paroxetine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	9.59e-05	0.000635	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.53e-05	0.000631	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	9.21e-05	0.000609	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	9.13e-05	0.000604	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	9.08e-05	0.000601	CbGpPWpGaD
Paroxetine—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	9.06e-05	0.0006	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	9.06e-05	0.0006	CbGpPWpGaD
Paroxetine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	9.06e-05	0.000599	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	9.04e-05	0.000598	CbGpPWpGaD
Paroxetine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	9.03e-05	0.000597	CbGpPWpGaD
Paroxetine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—dilated cardiomyopathy	8.94e-05	0.000592	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	8.84e-05	0.000585	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	8.66e-05	0.000573	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.65e-05	0.000573	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	8.54e-05	0.000565	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	8.52e-05	0.000564	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	8.46e-05	0.00056	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.4e-05	0.000556	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.4e-05	0.000556	CbGpPWpGaD
Paroxetine—HTR2A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	8.36e-05	0.000553	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.36e-05	0.000553	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.36e-05	0.000553	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.33e-05	0.000551	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.33e-05	0.000551	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGTR1—dilated cardiomyopathy	8.29e-05	0.000549	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.25e-05	0.000546	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.25e-05	0.000546	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—ADRB2—dilated cardiomyopathy	8.21e-05	0.000543	CbGpPWpGaD
Paroxetine—CHRM2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	8.21e-05	0.000543	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—RAC1—dilated cardiomyopathy	8.2e-05	0.000543	CbGpPWpGaD
Paroxetine—HTR2A—GPCR ligand binding—AGT—dilated cardiomyopathy	8.04e-05	0.000532	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	8.03e-05	0.000531	CbGpPWpGaD
Paroxetine—CHRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	8e-05	0.00053	CbGpPWpGaD
Paroxetine—CHRM3—GPCR ligand binding—AGT—dilated cardiomyopathy	7.98e-05	0.000528	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	7.96e-05	0.000527	CbGpPWpGaD
Paroxetine—CHRM2—GPCR ligand binding—AGT—dilated cardiomyopathy	7.9e-05	0.000523	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—ADRB2—dilated cardiomyopathy	7.86e-05	0.00052	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AGT—dilated cardiomyopathy	7.84e-05	0.000519	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.81e-05	0.000517	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.77e-05	0.000514	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.74e-05	0.000513	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	7.7e-05	0.00051	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.67e-05	0.000508	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.63e-05	0.000505	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.63e-05	0.000505	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.59e-05	0.000502	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.59e-05	0.000502	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.56e-05	0.000501	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.56e-05	0.000501	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.56e-05	0.000501	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.52e-05	0.000498	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.5e-05	0.000496	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.49e-05	0.000496	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.49e-05	0.000496	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.49e-05	0.000496	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.43e-05	0.000492	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	7.26e-05	0.00048	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	7.2e-05	0.000476	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PSEN2—dilated cardiomyopathy	7.17e-05	0.000475	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	7.09e-05	0.000469	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	7.06e-05	0.000467	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CXCR3—dilated cardiomyopathy	7.03e-05	0.000465	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—RAC1—dilated cardiomyopathy	7.02e-05	0.000465	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CXCR3—dilated cardiomyopathy	6.96e-05	0.000461	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.87e-05	0.000455	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	6.85e-05	0.000453	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.83e-05	0.000452	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.81e-05	0.000451	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	6.79e-05	0.000449	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	6.75e-05	0.000447	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.75e-05	0.000446	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	6.73e-05	0.000446	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—RAC1—dilated cardiomyopathy	6.72e-05	0.000445	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.71e-05	0.000444	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.65e-05	0.00044	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.65e-05	0.00044	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.46e-05	0.000428	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.43e-05	0.000425	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AGT—dilated cardiomyopathy	6.42e-05	0.000425	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.41e-05	0.000424	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.37e-05	0.000422	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGTR2—dilated cardiomyopathy	6.37e-05	0.000421	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCL2—dilated cardiomyopathy	6.37e-05	0.000421	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	6.34e-05	0.00042	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	6.31e-05	0.000418	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CXCR3—dilated cardiomyopathy	6.18e-05	0.000409	CbGpPWpGaD
Paroxetine—SLC6A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	6.17e-05	0.000409	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.13e-05	0.000406	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—RAC1—dilated cardiomyopathy	6.1e-05	0.000404	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.1e-05	0.000403	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AGT—dilated cardiomyopathy	6.09e-05	0.000403	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.08e-05	0.000402	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	6.02e-05	0.000398	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.99e-05	0.000396	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.92e-05	0.000392	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.87e-05	0.000388	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.84e-05	0.000386	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AGT—dilated cardiomyopathy	5.83e-05	0.000386	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.82e-05	0.000385	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGTR1—dilated cardiomyopathy	5.76e-05	0.000381	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADRB1—dilated cardiomyopathy	5.73e-05	0.000379	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.57e-05	0.000368	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.54e-05	0.000366	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.52e-05	0.000365	CbGpPWpGaD
Paroxetine—SLC6A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	5.47e-05	0.000362	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.47e-05	0.000362	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—RAF1—dilated cardiomyopathy	5.44e-05	0.00036	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	5.39e-05	0.000357	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	5.25e-05	0.000348	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGTR1—dilated cardiomyopathy	5.11e-05	0.000338	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.08e-05	0.000336	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.05e-05	0.000334	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PSEN2—dilated cardiomyopathy	5.03e-05	0.000333	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.98e-05	0.00033	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.9e-05	0.000324	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.85e-05	0.000321	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.76e-05	0.000315	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.73e-05	0.000313	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	4.73e-05	0.000313	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.72e-05	0.000312	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	4.7e-05	0.000311	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.67e-05	0.000309	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.64e-05	0.000307	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.55e-05	0.000301	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.52e-05	0.000299	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.51e-05	0.000298	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.51e-05	0.000298	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.51e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.48e-05	0.000297	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.48e-05	0.000297	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	4.47e-05	0.000296	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.47e-05	0.000296	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.47e-05	0.000296	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.46e-05	0.000295	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.43e-05	0.000293	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.43e-05	0.000293	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	4.39e-05	0.000291	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.32e-05	0.000286	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.3e-05	0.000284	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.28e-05	0.000284	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	4.27e-05	0.000283	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.24e-05	0.000281	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.23e-05	0.00028	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.19e-05	0.000277	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	4.17e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.17e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.15e-05	0.000275	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AGT—dilated cardiomyopathy	4.13e-05	0.000273	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.11e-05	0.000272	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	4.11e-05	0.000272	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AGT—dilated cardiomyopathy	4.09e-05	0.000271	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.06e-05	0.000269	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AGT—dilated cardiomyopathy	4.05e-05	0.000268	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—RAF1—dilated cardiomyopathy	4.05e-05	0.000268	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.04e-05	0.000267	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.02e-05	0.000266	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.99e-05	0.000264	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.98e-05	0.000264	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.85e-05	0.000255	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RAC1—dilated cardiomyopathy	3.77e-05	0.000249	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—EGFR—dilated cardiomyopathy	3.73e-05	0.000247	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RAC1—dilated cardiomyopathy	3.61e-05	0.000239	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AGT—dilated cardiomyopathy	3.6e-05	0.000238	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.47e-05	0.000229	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.45e-05	0.000228	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AGT—dilated cardiomyopathy	3.45e-05	0.000228	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.44e-05	0.000227	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGTR1—dilated cardiomyopathy	3.4e-05	0.000225	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GPX1—dilated cardiomyopathy	3.3e-05	0.000218	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.29e-05	0.000218	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.27e-05	0.000216	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.26e-05	0.000216	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.23e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CD36—dilated cardiomyopathy	3.21e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.9e-05	0.000192	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AGT—dilated cardiomyopathy	2.89e-05	0.000191	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.87e-05	0.00019	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.85e-05	0.000189	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.84e-05	0.000188	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GPX1—dilated cardiomyopathy	2.84e-05	0.000188	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.83e-05	0.000187	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.81e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.81e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.8e-05	0.000185	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.78e-05	0.000184	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.77e-05	0.000184	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CD36—dilated cardiomyopathy	2.76e-05	0.000183	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	2.72e-05	0.00018	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RAC1—dilated cardiomyopathy	2.55e-05	0.000169	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.54e-05	0.000168	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RAC1—dilated cardiomyopathy	2.53e-05	0.000168	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RAC1—dilated cardiomyopathy	2.51e-05	0.000166	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RAF1—dilated cardiomyopathy	2.5e-05	0.000165	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AGT—dilated cardiomyopathy	2.49e-05	0.000165	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGT—dilated cardiomyopathy	2.44e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGT—dilated cardiomyopathy	2.43e-05	0.000161	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGT—dilated cardiomyopathy	2.42e-05	0.00016	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	2.4e-05	0.000159	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGT—dilated cardiomyopathy	2.39e-05	0.000158	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RAF1—dilated cardiomyopathy	2.39e-05	0.000158	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	2.34e-05	0.000155	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	2.11e-05	0.000139	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.09e-05	0.000138	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.04e-05	0.000135	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	1.97e-05	0.000131	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.96e-05	0.00013	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	1.95e-05	0.000129	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.95e-05	0.000129	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.95e-05	0.000129	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.93e-05	0.000128	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	1.92e-05	0.000127	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	1.9e-05	0.000126	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	1.83e-05	0.000121	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	1.73e-05	0.000114	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	1.71e-05	0.000113	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—EGFR—dilated cardiomyopathy	1.71e-05	0.000113	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RAF1—dilated cardiomyopathy	1.69e-05	0.000112	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.68e-05	0.000111	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RAF1—dilated cardiomyopathy	1.68e-05	0.000111	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RAF1—dilated cardiomyopathy	1.66e-05	0.00011	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—EGFR—dilated cardiomyopathy	1.64e-05	0.000109	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—EGFR—dilated cardiomyopathy	1.16e-05	7.68e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.15e-05	7.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—EGFR—dilated cardiomyopathy	1.15e-05	7.62e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—EGFR—dilated cardiomyopathy	1.14e-05	7.54e-05	CbGpPWpGaD
